TIBET RHODIOLA PHARMACEUTICAL HOLDING CO.

Tibet Rhodiola Pharmaceutical Holding Co.

600211

CNE000000ZW7

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 03:30:00 20/06/2024 am IST			5-day change	1st Jan Change
34.18 ^CNY	-2.15%		-6.28%	-8.95%

26/04	Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
26/03	Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Tibet Rhodiola Pharmaceutical Holding Co. Approves the Proposal of Establishing Wholly-Owned Subsidiary

August 27, 2020

Tibet Rhodiola Pharmaceutical Holding Co. at the Board meeting held on August 27, 2020, approved the proposal of establishing wholly-owned subsidiary.

Latest news about Tibet Rhodiola Pharmaceutical Holding Co.

Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the First Quarter Ended March 31, 2024	26/04	CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03	CI
Chengdu Nuo´en Genomics Co., Ltd. announced that it has received funding from Jiaxing Anhong Zhifei Venture Capital Partnership (Limited Partnership), Tibet Rhodiola Pharmaceutical Holding Co.	14/01	CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Nine Months Ended September 30, 2023	26/23/26	CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Half Year Ended June 30, 2023	24/23/24	CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the First Quarter Ended March 31, 2023	27/23/27	CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Full Year Ended December 31, 2022	10/23/10	CI
Tibet Rhodiola Pharma Unit Becomes Authorized Marketer of Heart Drug	06/23/06	MT
Tibet Rhodiola Pharma Sees 81% Jump in 2022 Profit	26/23/26	MT
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Nine Months Ended September 30, 2022	27/22/27	CI
Tibet Rhodiola Pharma Wins License to Produce Chest Pain Tablets	26/22/26	MT
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Half Year Ended June 30, 2022	12/22/12	CI
Tibet Rhodiola Pharmaceutical Holding Co.(SHSE:600211) added to Shanghai Stock Exchange A Share Index	09/22/09	CI
Tibet Rhodiola Pharmaceutical Holding Co.(SHSE:600211) dropped from Shanghai Stock Exchange A Share Index	05/22/05	CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the First Quarter Ended March 31, 2022	26/22/26	CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Full Year Ended December 31, 2021	11/22/11	CI
Tibet Rhodiola Pharmaceutical Holding Co.(SHSE:600211) dropped from Shanghai Stock Exchange Health Care Sector Index	10/21/10	CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Nine Months Ended September 30, 2021	27/21/27	CI
Tibet Rhodiola Pharmaceutical Holding Co.(XSSC:600211) added to S&P Global BMI Index	20/21/20	CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Half Year Ended June 30, 2021	17/21/17	CI
Tibet Rhodiola Pharmaceutical Holding Co.(SHSE:600211) added to Shanghai Stock Exchange Health Care Sector Index	15/21/15	CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the First Quarter Ended March 31, 2021	26/21/26	CI
Tibet Rhodiola Pharmaceutical Holding Co. Reports Earnings Results for the Full Year Ended December 31, 2020	11/21/11	CI
Tibet Rhodiola Pharmaceutical : Stemirna COVID-19 vaccine candidate obtains clinical trial approval in China	05/21/05	RE
Shanghai Fosun Pharmaceutical : Fosun Pharma to buy 100 million doses of BioNTech's COVID-19 vaccine for mainland China	16/20/16	RE

Chart Tibet Rhodiola Pharmaceutical Holding Co.

Duration

Period

Chart Tibet Rhodiola Pharmaceutical Holding Co.

More charts

TIBET RHODIOLA PHARMACEUTICAL HOLDING CO. is a China-based company principally engaged in the production and distribution of pharmaceuticals. The Company operates its businesses through the distribution of proprietary drug products, as well as the processing of pharmaceuticals and others. The Company conducts its businesses primarily in South China, North China, East China, Central China and overseas markets.

Sector

Pharmaceuticals

Calendar

15/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Tibet Rhodiola Pharmaceutical Holding Co.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

34.18

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TIBET RHODIOLA PHARMACEUTICAL HOLDING CO.	-8.95%	1.55B
ELI LILLY AND COMPANY	+51.99%	803B
JOHNSON & JOHNSON	-5.72%	351B
MERCK & CO., INC.	+18.94%	324B
ABBVIE INC.	+11.07%	303B
ASTRAZENECA PLC	+16.96%	243B
ROCHE HOLDING AG	+2.25%	228B
NOVARTIS AG	+11.15%	217B
AMGEN INC.	+7.59%	164B
PFIZER, INC.	-3.65%	155B

Other Pharmaceuticals